Skip to content
Screener

Viking Therapeutics VKTX Q1 2025 earnings

Reported April 23, 2025 · After market close

Revenue-
EPS-$0.41Miss by $0.07
EPS estimate-$0.34

Next report

Oct 28, 2026 (in a month)
EPS estimate-$1.07

Financials

Q1 2025

Income statement

See full
Revenue-—
Operating income-$55.5M-62.8%
Net income-$45.6M-66.8%
EPS (diluted)-$0.41-57.7%

Balance sheet

See full
Cash & equivalents$37.9M-80.6%
Total debt$1.0M-15.3%
Total equity$846.9M-9.3%
Total assets$867.0M-10.4%

Cash flow

See full
Operating cash flow-$52.3M-753%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.71B-68.0%
Enterprise value$2.67B-67.7%

Returns & leverage

See full
Return on equity-14.4%-2.2pp
Debt / equity0×0.0×
Current ratio44.2×+14.8×

FAQ

When did Viking Therapeutics report Q1 2025 earnings?
Viking Therapeutics (VKTX) reported Q1 2025 earnings on April 23, 2025 after market close.
What were Viking Therapeutics's Q1 2025 revenue and EPS?
Viking Therapeutics reported revenue of - and eps of $-0.41 for Q1 2025.
Did Viking Therapeutics beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.34 by $0.07.
How did Viking Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 57.7% from $-0.26.
Where can I find Viking Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-057337) and the 10-Q periodic report (0000950170-25-058129) directly on SEC EDGAR. The filing index links above go to sec.gov.